Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.47 |
| ▸ | F2R | P25116 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.41 |
| ▸ | CALCR | P30988 | 4/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | CTSE | P14091 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30272450 | 0.96 | F2 (0.46) | MC4RF2F2ROPRK1NMUR2 | |
| SCHEMBL30827585 | 0.91 | MC4R (0.46) | MC4RF2F2ROPRK1CTSD | |
| SCHEMBL30827588 | 0.90 | MC4R (0.47) | MC4RF2F2RCALCRCTSD | |
| SCHEMBL30272526 | 0.89 | F2 (0.58) | MC4RF2OPRK1NMUR2CALCR | |
| SCHEMBL30272525 | 0.89 | F2 (0.56) | MC4RF2OPRK1NMUR2CALCR | |
| SCHEMBL30272496 | 0.89 | KDM1A (0.48) | MC4RF2NMUR2 | |
| SCHEMBL30258236 | 0.89 | F2 (0.45) | MC4RF2F2ROPRK1CALCR | |
| SCHEMBL31174229 | 0.86 | CALCR (0.57) | MC4RF2CALCRAPLNR | |
| SCHEMBL29630560 | 0.86 | OPRK1 (0.46) | MC4RF2ROPRK1CTSD | |
| SCHEMBL29590547 | 0.86 | OPRK1 (0.46) | MC4RF2ROPRK1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115746104-A | Preparation method of Bulevirtide | 深圳市健翔生物制药有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115746102-A | Method for preparing Bulevirtide by combining solid phase with liquid phase | 深圳市健翔生物制药有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115746103-A | Preparation method of Bulevirtide | 深圳市健翔生物制药有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115746102-A | Method for preparing Bulevirtide by combining solid phase with liquid phase | 深圳市健翔生物制药有限公司 | 2023-03-07 | — | — | CN | disclosed |